ALNY News Alnylam to Webcast Presentation at the Lehman Brothers Tenth Annual Global Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the Lehman Brothers Tenth Annual Global Healthcare Conference on Monday, March 19, 2007 at 2:00 p.m. ET at the Loews Miami Beach Hotel in Miami, Florida.
A live audio webcast of the presentation will be available on the “Investors” section of the company’s website, www.alnylam.com. A replay of the presentation will be posted on the Alnylam website within 48 hours after the event, and will be archived for 14 days.
About Alnylam
Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is applying its therapeutic expertise in RNAi to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies, the current major classes of drugs. Alnylam is building a pipeline of RNAi therapeutics; its lead program is in Phase I human clinical trials for the treatment of respiratory syncytial virus (RSV) infection, which is the leading cause of hospitalization in infants in the U.S. The company’s leadership position in fundamental patents, technology, and know-how relating to RNAi has enabled it to form major alliances with leading companies including Merck, Medtronic, Novartis, and Biogen Idec. The company, founded in 2002, maintains global headquarters in Cambridge, Massachusetts, and has an additional operating unit in Kulmbach, Germany. For more information, visit www.alnylam.com.
